Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by StockHawk1on Oct 28, 2022 2:41pm

97 Views

Post# 35056556

AGN enters Clinical Trial Agreement with Yale University

Algernon Pharmaceuticals (AGN.c AGNPF) is trading in the green after announcing today that it has entered a Clinical Trial Agreement with Yale University for the investigation of DMT for the treatment of depression.

Under the agreement, AGN will provide DMT for the study and will jointly own intellectual property that arises from the study.

AGN will also receive data from the study, which could help it with its DMT stroke-treatment research.

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-enters-clinical-trial-110000717.html

AGN 4% @ $2.88, MC $6.791M

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for Sept. 19, 2024